Cargando…

Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria

This prospective cross-sectional study compared the diagnostic accuracy of human epididymal protein 4 (HE4) with cancer antigen 125 (CA 125) and validates the risk of malignancy algorithm (ROMA) in differentiating benign from malignant ovarian tumours. The study population included 112 women with an...

Descripción completa

Detalles Bibliográficos
Autores principales: Shittu, Khadijah Adebisi, Rabiu, Kabiru Afolarin, Akinola, Oluwarotimi Ireti, Ahmed, Saheed Bolaji, Adewunmi, Adeniyi Abiodun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393307/
https://www.ncbi.nlm.nih.gov/pubmed/37533954
http://dx.doi.org/10.3332/ecancer.2023.1568
_version_ 1785083139904765952
author Shittu, Khadijah Adebisi
Rabiu, Kabiru Afolarin
Akinola, Oluwarotimi Ireti
Ahmed, Saheed Bolaji
Adewunmi, Adeniyi Abiodun
author_facet Shittu, Khadijah Adebisi
Rabiu, Kabiru Afolarin
Akinola, Oluwarotimi Ireti
Ahmed, Saheed Bolaji
Adewunmi, Adeniyi Abiodun
author_sort Shittu, Khadijah Adebisi
collection PubMed
description This prospective cross-sectional study compared the diagnostic accuracy of human epididymal protein 4 (HE4) with cancer antigen 125 (CA 125) and validates the risk of malignancy algorithm (ROMA) in differentiating benign from malignant ovarian tumours. The study population included 112 women with an ultrasound diagnosis of an adnexal mass, out of whom 49 women had a diagnosis of ovarian cancer following optimal debulking surgery, and 63 women had a diagnosis of benign ovarian tumour. All diagnosis was confirmed by histopathological analysis. Serum HE4 and CA 125 were assessed preoperatively according to the manufacturer’s instructions. CA 125 and HE4 cut-offs were 35 U/mL and 70 pM/L respectively. Serum CA 125 and HE4 were significantly higher in ovarian cancer patients compared to those with benign ovarian tumours (p < 0.001 and p < 0.000, respectively). HE4 had higher sensitivity (77.5% versus 69.4%), specificity (96.8% versus 82.5%), positive predictive value (PPV) (95% versus 75.6%) and negative predictive value (84.7% versus 77.6%) than CA 125. When the two markers were combined with each other in the ROMA index, Specificity and PPV reached 100% each. In the receiver operative characteristics analysis, the area under the curve for CA 125 was 0.679 (95% CI 0.566–0.791, p = 0.001), HE4 was 0.845 (95% CI 0.760–0.930, p = 0.000) and ROMA was 0.902 (95% CI 0.851–0.998, p = 0.000) and this was statistically significant (p < 0.001). Conclusively, HE4 performed better than CA 125 in differentiating benign from malignant ovarian tumours and the combination of the two biomarkers improved the detection of ovarian cancer. In addition, the cut off values corresponding to the highest accuracy for CA 125 and HE4 were 126 U/mL and 42 pM/L respectively in this study. The value for CA 125 is much higher while that of HE4 is much lower than the reference values obtained predominantly from the white population.
format Online
Article
Text
id pubmed-10393307
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-103933072023-08-02 Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria Shittu, Khadijah Adebisi Rabiu, Kabiru Afolarin Akinola, Oluwarotimi Ireti Ahmed, Saheed Bolaji Adewunmi, Adeniyi Abiodun Ecancermedicalscience Research This prospective cross-sectional study compared the diagnostic accuracy of human epididymal protein 4 (HE4) with cancer antigen 125 (CA 125) and validates the risk of malignancy algorithm (ROMA) in differentiating benign from malignant ovarian tumours. The study population included 112 women with an ultrasound diagnosis of an adnexal mass, out of whom 49 women had a diagnosis of ovarian cancer following optimal debulking surgery, and 63 women had a diagnosis of benign ovarian tumour. All diagnosis was confirmed by histopathological analysis. Serum HE4 and CA 125 were assessed preoperatively according to the manufacturer’s instructions. CA 125 and HE4 cut-offs were 35 U/mL and 70 pM/L respectively. Serum CA 125 and HE4 were significantly higher in ovarian cancer patients compared to those with benign ovarian tumours (p < 0.001 and p < 0.000, respectively). HE4 had higher sensitivity (77.5% versus 69.4%), specificity (96.8% versus 82.5%), positive predictive value (PPV) (95% versus 75.6%) and negative predictive value (84.7% versus 77.6%) than CA 125. When the two markers were combined with each other in the ROMA index, Specificity and PPV reached 100% each. In the receiver operative characteristics analysis, the area under the curve for CA 125 was 0.679 (95% CI 0.566–0.791, p = 0.001), HE4 was 0.845 (95% CI 0.760–0.930, p = 0.000) and ROMA was 0.902 (95% CI 0.851–0.998, p = 0.000) and this was statistically significant (p < 0.001). Conclusively, HE4 performed better than CA 125 in differentiating benign from malignant ovarian tumours and the combination of the two biomarkers improved the detection of ovarian cancer. In addition, the cut off values corresponding to the highest accuracy for CA 125 and HE4 were 126 U/mL and 42 pM/L respectively in this study. The value for CA 125 is much higher while that of HE4 is much lower than the reference values obtained predominantly from the white population. Cancer Intelligence 2023-07-05 /pmc/articles/PMC10393307/ /pubmed/37533954 http://dx.doi.org/10.3332/ecancer.2023.1568 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Shittu, Khadijah Adebisi
Rabiu, Kabiru Afolarin
Akinola, Oluwarotimi Ireti
Ahmed, Saheed Bolaji
Adewunmi, Adeniyi Abiodun
Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
title Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
title_full Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
title_fullStr Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
title_full_unstemmed Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
title_short Comparison of the diagnostic accuracy of HE4 with CA125 and validation of the ROMA index in differentiating malignant and benign epithelial ovarian tumours among patients in Lagos, Nigeria
title_sort comparison of the diagnostic accuracy of he4 with ca125 and validation of the roma index in differentiating malignant and benign epithelial ovarian tumours among patients in lagos, nigeria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10393307/
https://www.ncbi.nlm.nih.gov/pubmed/37533954
http://dx.doi.org/10.3332/ecancer.2023.1568
work_keys_str_mv AT shittukhadijahadebisi comparisonofthediagnosticaccuracyofhe4withca125andvalidationoftheromaindexindifferentiatingmalignantandbenignepithelialovariantumoursamongpatientsinlagosnigeria
AT rabiukabiruafolarin comparisonofthediagnosticaccuracyofhe4withca125andvalidationoftheromaindexindifferentiatingmalignantandbenignepithelialovariantumoursamongpatientsinlagosnigeria
AT akinolaoluwarotimiireti comparisonofthediagnosticaccuracyofhe4withca125andvalidationoftheromaindexindifferentiatingmalignantandbenignepithelialovariantumoursamongpatientsinlagosnigeria
AT ahmedsaheedbolaji comparisonofthediagnosticaccuracyofhe4withca125andvalidationoftheromaindexindifferentiatingmalignantandbenignepithelialovariantumoursamongpatientsinlagosnigeria
AT adewunmiadeniyiabiodun comparisonofthediagnosticaccuracyofhe4withca125andvalidationoftheromaindexindifferentiatingmalignantandbenignepithelialovariantumoursamongpatientsinlagosnigeria